News
‘It’s fantastic to make a discovery, but even cooler if we can really help patients’
From a scientific idea to a multi-million euro investment: the successes of the many NWO Venture Challenge alumni reveal what can be achieved if you take science out of the lab onto the market.
Venture Challenge Fall 2022 Now open for applications!
The proven Venture Challenge coaching programme focuses on developing your initial idea into a solid business case with boot camps, 1-on-1 coaching and mentoring.
Meet the teams of the Venture Challenge Spring 2022
Last week five teams started their Venture Challenge adventure. In the first three-day workshop the highly motivated teams worked on their customer value proposition, long-term vision and competitive positioning.
Quell Therapeutics and Cellistic™ enter a strategic collaboration
After Ncardia launched its affiliate company Cellistic last week, dedicated to making large-scale allogeneic cell therapy production a reality, they are proud to now enter a strategic collaboration with Quell Therapeutics, to develop an iPSC-derived allogeneic T-regulatory cell therapy platform.
Yesterday an Inspiring MedtechMeeting Took Place!
MedtechPartners is a strong network of experts in the medical technology industry. At this meeting, promising start-ups pitched their innovation and were matched to the partners and audience. The MedtechMeeting ended with networking drinks. All in all it was a great succes!
Anya Biotech wins the Proefdiervrij Venture Challenge 2022
The Hague - 22 April 2022. At the Proefdiervrij Event Anya Biotech was announced the winner of the 2nd edition of the Proefdiervrij Venture Challenge. Harsha Devalla, Marc Roelofs and Sander van Leeuwe of Anya Biotech develop animal-free re
Venture Challenge Fall 2022 open for applications!
Curious what the Venture Challenge may bring you? This is what last year's alumni say about it.
STENTiT raises €1.8 Million in Seed Round
Eindhoven, The Netherlands, 25 April 2022 – Venture Challenge alumnus STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million see
Ncardia launches Cellistic, an iPSC cell therapy CDMO
Ncardia launches CellisticTM, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.
Life Sciences & Health Krijgt Boost na Gehonoreerde Groeifonds Voorstellen!
Een investering van € 5 miljard en daarnaast een reservering van € 1,3 miljard voor in totaal 28 projecten moeten zorgen voor duurzame economische groei in Nederland.